RPTX reparerx.com: Enterprise Value to EBITDA Ratio

Repare Therapeutics (RPTX) creates targeted cancer treatments by utilizing AI to identify genetic vulnerabilities, while patent protection and alliances with industry behemoths guarantee commercial success. This chart of the process's market value captures the figure at 0.00. Repare Therapeutics (RPTX) implements green chemistry and waste recycling principles while simultaneously developing an aggressive R&D pipeline featuring innovative inhibitors for precision therapy.

RPTX (Repare Therapeutics, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 02/07/2026

Comprehensive metric breakdowns and analytics for reparerx.com (RPTX)

- stock price and consensus target price:

Stock Quotes Repare Rx|RPTX - Average Forecast Price

- company stock capitalization data:

Market Valuation Repare Therapeutics Inc|RPTX - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Repare Therapeutics|RPTX - Total Net Assets|Market Capitalization to Book Value Ratio reparerx.com|RPTX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

RPTX - Company Net Income|Projected Future Earnings Repare Therapeutics|RPTX - Price to Earnings Multiple|Projected Price to Earnings Repare Therapeutics|RPTX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Repare Therapeutics Inc|RPTX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Repare Therapeutics|RPTX - Earnings per share for the trailing year|Quarterly EPS earnings growth reparerx.com|RPTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Repare Therapeutics

Basic company analysis:Repare Rx RPTX

Repare Therapeutics (RPTX) utilizes the SNIPRx AI platform to develop targeted oncology therapies, monetizing its intellectual property through licensing agreements with pharmaceutical behemoths. By analyzing the company's current EV/EBITDA trend, an investor assesses the total enterprise value (market capitalization and debt) relative to operating profit before depreciation and amortization, which determines the asset's degree of overvaluation and the efficiency of debt load management while scaling biotech projects.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|BDTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple